Diabetic gastroparesis

Therapeutic options

Uazman Alam, Omar Asghar, Rayaz Malik

Research output: Contribution to journalReview article

16 Citations (Scopus)

Abstract

Gastroparesis is a condition characterized by delayed gastric emptying and the most common known underlying cause is diabetes mellitus. Symptoms include nausea, vomiting, abdominal fullness, and early satiety, which impact to varying degrees on the patient's quality of life. Symptoms and deficits do not necessarily relate to each other, hence despite significant abnormalities in gastric emptying, some individuals have only minimal symptoms and, conversely, severe symptoms do not always relate to measures of gastric emptying. Prokinetic agents such as metoclopramide, domperidone, and erythromycin enhance gastric motility and have remained the mainstay of treatment for several decades, despite unwanted side effects and numerous drug interactions. Mechanical therapies such as endoscopic pyloric botulinum toxin injection, gastric electrical stimulation, and gastrostomy or jejunostomy are used in intractable diabetic gastroparesis (DG), refractory to prokinetic therapies. Mitemcinal and TZP-101 are novel investigational motilin receptor and ghrelin agonists, respectively, and show promise in the treatment of DG. The aim of this review is to provide an update on prokinetic and mechanical therapies in the treatment of DG.

Original languageEnglish
Pages (from-to)32-43
Number of pages12
JournalDiabetes Therapy
Volume1
Issue number1
DOIs
Publication statusPublished - 1 Jan 2010

Fingerprint

Gastroparesis
Gastric Emptying
Stomach
Therapeutics
Domperidone
Jejunostomy
Metoclopramide
Ghrelin
Gastrostomy
Botulinum Toxins
Erythromycin
Drug-Related Side Effects and Adverse Reactions
Drug Interactions
Nausea
Electric Stimulation
Vomiting
Diabetes Mellitus
Quality of Life
Injections

Keywords

  • diabetic gastroparesis
  • gastric electrical stimulation
  • ghrelin
  • mechanical therapy
  • prokinetic therapy

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Diabetic gastroparesis : Therapeutic options. / Alam, Uazman; Asghar, Omar; Malik, Rayaz.

In: Diabetes Therapy, Vol. 1, No. 1, 01.01.2010, p. 32-43.

Research output: Contribution to journalReview article

Alam, Uazman ; Asghar, Omar ; Malik, Rayaz. / Diabetic gastroparesis : Therapeutic options. In: Diabetes Therapy. 2010 ; Vol. 1, No. 1. pp. 32-43.
@article{f8dbcc05574243268f6ae0c20b3bb16c,
title = "Diabetic gastroparesis: Therapeutic options",
abstract = "Gastroparesis is a condition characterized by delayed gastric emptying and the most common known underlying cause is diabetes mellitus. Symptoms include nausea, vomiting, abdominal fullness, and early satiety, which impact to varying degrees on the patient's quality of life. Symptoms and deficits do not necessarily relate to each other, hence despite significant abnormalities in gastric emptying, some individuals have only minimal symptoms and, conversely, severe symptoms do not always relate to measures of gastric emptying. Prokinetic agents such as metoclopramide, domperidone, and erythromycin enhance gastric motility and have remained the mainstay of treatment for several decades, despite unwanted side effects and numerous drug interactions. Mechanical therapies such as endoscopic pyloric botulinum toxin injection, gastric electrical stimulation, and gastrostomy or jejunostomy are used in intractable diabetic gastroparesis (DG), refractory to prokinetic therapies. Mitemcinal and TZP-101 are novel investigational motilin receptor and ghrelin agonists, respectively, and show promise in the treatment of DG. The aim of this review is to provide an update on prokinetic and mechanical therapies in the treatment of DG.",
keywords = "diabetic gastroparesis, gastric electrical stimulation, ghrelin, mechanical therapy, prokinetic therapy",
author = "Uazman Alam and Omar Asghar and Rayaz Malik",
year = "2010",
month = "1",
day = "1",
doi = "10.1007/s13300-010-0010-8",
language = "English",
volume = "1",
pages = "32--43",
journal = "Diabetes Therapy",
issn = "1869-6953",
publisher = "Springer Publishing Company",
number = "1",

}

TY - JOUR

T1 - Diabetic gastroparesis

T2 - Therapeutic options

AU - Alam, Uazman

AU - Asghar, Omar

AU - Malik, Rayaz

PY - 2010/1/1

Y1 - 2010/1/1

N2 - Gastroparesis is a condition characterized by delayed gastric emptying and the most common known underlying cause is diabetes mellitus. Symptoms include nausea, vomiting, abdominal fullness, and early satiety, which impact to varying degrees on the patient's quality of life. Symptoms and deficits do not necessarily relate to each other, hence despite significant abnormalities in gastric emptying, some individuals have only minimal symptoms and, conversely, severe symptoms do not always relate to measures of gastric emptying. Prokinetic agents such as metoclopramide, domperidone, and erythromycin enhance gastric motility and have remained the mainstay of treatment for several decades, despite unwanted side effects and numerous drug interactions. Mechanical therapies such as endoscopic pyloric botulinum toxin injection, gastric electrical stimulation, and gastrostomy or jejunostomy are used in intractable diabetic gastroparesis (DG), refractory to prokinetic therapies. Mitemcinal and TZP-101 are novel investigational motilin receptor and ghrelin agonists, respectively, and show promise in the treatment of DG. The aim of this review is to provide an update on prokinetic and mechanical therapies in the treatment of DG.

AB - Gastroparesis is a condition characterized by delayed gastric emptying and the most common known underlying cause is diabetes mellitus. Symptoms include nausea, vomiting, abdominal fullness, and early satiety, which impact to varying degrees on the patient's quality of life. Symptoms and deficits do not necessarily relate to each other, hence despite significant abnormalities in gastric emptying, some individuals have only minimal symptoms and, conversely, severe symptoms do not always relate to measures of gastric emptying. Prokinetic agents such as metoclopramide, domperidone, and erythromycin enhance gastric motility and have remained the mainstay of treatment for several decades, despite unwanted side effects and numerous drug interactions. Mechanical therapies such as endoscopic pyloric botulinum toxin injection, gastric electrical stimulation, and gastrostomy or jejunostomy are used in intractable diabetic gastroparesis (DG), refractory to prokinetic therapies. Mitemcinal and TZP-101 are novel investigational motilin receptor and ghrelin agonists, respectively, and show promise in the treatment of DG. The aim of this review is to provide an update on prokinetic and mechanical therapies in the treatment of DG.

KW - diabetic gastroparesis

KW - gastric electrical stimulation

KW - ghrelin

KW - mechanical therapy

KW - prokinetic therapy

UR - http://www.scopus.com/inward/record.url?scp=85027922586&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85027922586&partnerID=8YFLogxK

U2 - 10.1007/s13300-010-0010-8

DO - 10.1007/s13300-010-0010-8

M3 - Review article

VL - 1

SP - 32

EP - 43

JO - Diabetes Therapy

JF - Diabetes Therapy

SN - 1869-6953

IS - 1

ER -